M
Marilyn Borgman
Researcher at Cleveland Clinic
Publications - 14
Citations - 2601
Marilyn Borgman is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Statin & Coronary artery disease. The author has an hindex of 14, co-authored 14 publications receiving 2125 citations.
Papers
More filters
Journal ArticleDOI
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls,Stephen J. Nicholls,Rishi Puri,Todd J. Anderson,Christie M. Ballantyne,Leslie Cho,John J.P. Kastelein,Wolfgang Koenig,Wolfgang Koenig,Ransi Somaratne,Helina Kassahun,Jingyuan Yang,Scott M. Wasserman,Rob Scott,Imre Ungi,Jakub Podolec,Antonius Oude Ophuis,Jan H. Cornel,Marilyn Borgman,Danielle M. Brennan,Steven E. Nissen +20 more
TL;DR: Among patients with angiographic coronary disease treated with statins, addition of evolocumab, compared with placebo, resulted in a greater decrease in PAV after 76 weeks of treatment, and further studies are needed to assess the effects of PCSK9 inhibition on clinical outcomes.
Journal ArticleDOI
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Stephen J. Nicholls,Christie M. Ballantyne,Philip J. Barter,M. John Chapman,Raimund Erbel,Peter Libby,Joel S. Raichlen,Kiyoko Uno,Marilyn Borgman,Kathy Wolski,Steven E. Nissen +10 more
TL;DR: Maximal doses of rosuVastatin and atorvastatin resulted in significant regression of coronary atherosclerosis, with a low incidence of laboratory abnormalities and cardiovascular events.
Journal ArticleDOI
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Stephen J. Nicholls,Christie M. Ballantyne,Philip J. Barter,M.J. Chapman,Raimund Erbel,Peter Libby,Joel Raichlen,Kiyoko Uno,Marilyn Borgman,Kathy Wolski,Steven E. Nissen +10 more
Journal ArticleDOI
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Stephen J. Nicholls,Allan Gordon,Jan Johansson,Kathy Wolski,Christie M. Ballantyne,John J.P. Kastelein,Allen J. Taylor,Marilyn Borgman,Steven E. Nissen +8 more
TL;DR: Administration of RVX-208 for 12 weeks was associated with increases in apoA-I, HDL-C, and concentration of large HDL particles, consistent with facilitation of cholesterol mobilization, suggesting that peak pharmacological effect has not been achieved by the end of the 12-week study.
Journal ArticleDOI
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial A Randomized Clinical Trial
Stephen J. Nicholls,Stephen J. Nicholls,Rishi Puri,Christie M. Ballantyne,Christie M. Ballantyne,J. Wouter Jukema,John J.P. Kastelein,Wolfgang Koenig,Wolfgang Koenig,R. Scott Wright,David Kallend,Peter L.J. Wijngaard,Marilyn Borgman,Kathy Wolski,Steven E. Nissen +14 more
TL;DR: Among patients with an acute coronary syndrome, infusing MDCO-216 did not produce an incremental plaque regression in the setting of contemporary statin therapy.